Matriptase-2, a serine protease expressed in hepatocytes, is a negative regulator of hepcidin expression. The purpose of the study was to investigate the interaction of matriptase-2 with hemojuvelin protein in vivo. Mice lacking the matriptase-2 proteolytic activity (mask mice) display decreased content of hemojuvelin protein. Vice versa, the absence of hemojuvelin results in decreased liver content of matriptase-2, indicating that the two proteins interact. To further characterize the role of matriptase-2, we investigated iron metabolism in mask mice fed experimental diets. Administration of iron-enriched diet increased liver iron stores as well as hepcidin expression. Treatment of iron-overloaded mask mice with erythropoietin increased hemoglobin and hematocrit, indicating that the response to erythropoietin is intact in mask mice. Feeding of an iron-deficient diet to mask mice significantly increased spleen weight as well as the splenic content of erythroferrone and transferrin receptor proteins, indicating stress erythropoiesis. Liver hepcidin expression was decreased; expression of Id1 was not changed. Overall, the results suggest a complex interaction between matriptase-2 and hemojuvelin, and demonstrate that hepcidin can to some extent be regulated even in the absence of matriptase-2 proteolytic activity.
- MeSH
- deficit železa MeSH
- dietní železo farmakologie MeSH
- erythropoetin farmakologie MeSH
- GPI-vázané proteiny biosyntéza nedostatek genetika fyziologie MeSH
- hepcidiny biosyntéza genetika MeSH
- inhibitor diferenciace 1 biosyntéza genetika MeSH
- játra metabolismus MeSH
- kostní morfogenetický protein 6 biosyntéza genetika MeSH
- membránové proteiny nedostatek genetika fyziologie MeSH
- myši inbrední C57BL MeSH
- myši knockoutované MeSH
- myši MeSH
- orgánová specificita MeSH
- přetížení železem metabolismus MeSH
- promotorové oblasti (genetika) genetika MeSH
- protein hemochromatózy biosyntéza nedostatek genetika fyziologie MeSH
- proteinové domény MeSH
- regulace genové exprese účinky léků MeSH
- rekombinantní proteiny metabolismus MeSH
- serinové endopeptidasy nedostatek genetika fyziologie MeSH
- slezina metabolismus MeSH
- železo MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Optimal discrimination between leukemic blasts and normal B-cell precursors (BCP) is critical for treatment monitoring in BCP acute lymphoblastic leukemia (ALL); thus identification of markers differentially expressed on normal BCP and leukemic blasts is required. METHODS: Multicenter analysis of CD73, CD86 and CD304 expression levels was performed in 282 pediatric BCP-ALL patients vs. normal bone marrow BCP, using normalized median fluorescence intensity (nMFI) values. RESULTS: CD73 was expressed at abnormally higher levels (vs. pooled normal BCP) at diagnosis in 71/108 BCP-ALL patients (66%), whereas CD304 and CD86 in 119/202 (59%) and 58/100 (58%) patients, respectively. Expression of CD304 was detected at similar percentages in common-ALL and pre-B-ALL, while found at significantly lower frequencies in pro-B-ALL. A significant association (p = 0.009) was found between CD304 expression and the presence of the ETV6-RUNX1 fusion gene. In contrast, CD304 showed an inverse association with MLL gene rearrangements (p = 0.01). The expression levels of CD73, CD86 and CD304 at day 15 after starting therapy (MRD15) were stable or higher than at diagnosis in 35/37 (95%), 40/56 (71%) and 19/41 (46%) cases investigated, respectively. This was also associated with an increased mean nMFI at MRD15 vs. diagnosis of +24 and +3 nMFI units for CD73 and CD86, respectively. In addition, gain of expression of CD73 and CD86 at MRD15 for cases that were originally negative for these markers at diagnosis was observed in 16% and 18% of cases, respectively. Of note, CD304 remained aberrantly positive in 63% of patients, despite its levels of expression decreased at follow-up in 54% of cases. CONCLUSIONS: Here we show that CD73, CD86 and CD304 are aberrantly (over)expressed in a substantial percentage of BCP-ALL patients and that their expression profile remains relatively stable early after starting therapy, supporting their potential contribution to improved MRD analysis by flow cytometry.
- MeSH
- 5'-nukleotidasa analýza biosyntéza MeSH
- antigeny CD86 analýza biosyntéza MeSH
- dítě MeSH
- GPI-vázané proteiny analýza biosyntéza MeSH
- lidé MeSH
- nádorové biomarkery analýza MeSH
- neuropilin-1 analýza biosyntéza MeSH
- pre-B-buněčná leukemie patologie MeSH
- předškolní dítě MeSH
- prekurzorové B-lymfoidní buňky patologie MeSH
- reziduální nádor MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
Omentin is a novel adipokine with insulin-sensitizing effects expressed predominantly in visceral fat. We investigated serum omentin levels and its mRNA expression in subcutaneous adipose tissue (SCAT) of 11 women with type 2 diabetes mellitus (T2DM), 37 obese non-diabetic women (OB) and 26 healthy lean women (C) before and after various weight loss interventions: 2-week very-low-calorie diet (VLCD), 3-month regular exercise and laparoscopic sleeve gastrectomy (LSG). At baseline, both T2DM and OB groups had decreased serum omentin concentrations compared with C group while omentin mRNA expression in SCAT did not significantly differ among the groups. Neither VLCD nor exercise significantly affected serum omentin concentrations and its mRNA expression in SCAT of OB or T2DM group. LSG significantly increased serum omentin levels in OB group. In contrast, omentin mRNA expression in SCAT was significantly reduced after LSG. Baseline fasting serum omentin levels in a combined group of the studied subjects (C, OB, T2DM) negatively correlated with BMI, CRP, insulin, LDL-cholesterol, triglycerides and leptin and were positively related to HDL-cholesterol. Reduced circulating omentin levels could play a role in the etiopathogenesis of obesity and T2DM. The increase in circulating omentin levels and the decrease in omentin mRNA expression in SCAT of obese women after LSG might contribute to surgery-induced metabolic improvements and sustained reduction of body weight.
- MeSH
- cytokiny biosyntéza krev MeSH
- diabetes mellitus 2. typu krev epidemiologie terapie MeSH
- dospělí MeSH
- gastrektomie metody MeSH
- GPI-vázané proteiny biosyntéza krev MeSH
- kalorická restrikce metody MeSH
- laparoskopie metody MeSH
- lektiny biosyntéza krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- messenger RNA biosyntéza MeSH
- morbidní obezita krev epidemiologie terapie MeSH
- následné studie MeSH
- podkožní tuk metabolismus MeSH
- pohybová aktivita fyziologie MeSH
- regulace genové exprese MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
The prognosis of newly diagnosed colorectal cancer patients relies mostly on tumor-node metastasis classification. However, analyses of tumor-infiltrating lymphocytes and several molecular markers have also shown promising prognostic value. Mutations in the proto-oncogene KRAS, which occur early in colorectal carcinogenesis, have been demonstrated to be common in human colorectal cancer (CRC); however, their prognostic significance remains controversial. We examined the correlations between KRAS mutational status and tumor-infiltrating immune cells with respect to CRC recurrence. Mutations in KRAS were identified in 45.5% of the primary carcinomas in our cohort of patients: 65% in codon 12 and 35% in codon 13. Although codon 13 KRAS mutations were associated with disease relapse, they were present in both disease-free and relapsed patients. However, disease-free and relapsed patients differed markedly in their patterns of tumor-infiltrating immune cells. There was a trend toward decreased density of tumor-infiltrating lymphocytes (TILs) within the group of relapsed cases. In addition, relapsed patients with codon 13 mutations had markedly lower levels of tumor-infiltrating mature DC-LAMP(+) dendritic cells (DCs) and higher frequency of CD1a(+) cells compared with disease-free patients. Our data suggest that CRC patients with low levels of TILs, a high CD1a(+)/DC-LAMP(+) tumor-infiltrating DC ratio, and a KRAS mutation in codon 13 are at a high risk of disease recurrence.
- MeSH
- antigeny CD1 biosyntéza MeSH
- buněčná diferenciace genetika MeSH
- časná detekce nádoru MeSH
- dendritické buňky imunologie metabolismus patologie MeSH
- genetické asociační studie MeSH
- GPI-vázané proteiny biosyntéza MeSH
- karcinom diagnóza genetika patologie patofyziologie MeSH
- kolorektální nádory diagnóza genetika patologie patofyziologie MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- molekuly buněčné adheze neuronové biosyntéza MeSH
- mutace genetika MeSH
- mutační analýza DNA MeSH
- nádorové biomarkery genetika MeSH
- následné studie MeSH
- pohyb buněk genetika MeSH
- prognóza MeSH
- protoonkogenní proteiny genetika MeSH
- ras proteiny genetika MeSH
- tumor infiltrující lymfocyty imunologie metabolismus patologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH